BR112012029881A2 - combinação de anticorpos anti-envelope e anticorpos anti-receptor para o tratamento e a presenção de infecção por hcv - Google Patents

combinação de anticorpos anti-envelope e anticorpos anti-receptor para o tratamento e a presenção de infecção por hcv

Info

Publication number
BR112012029881A2
BR112012029881A2 BR112012029881A BR112012029881A BR112012029881A2 BR 112012029881 A2 BR112012029881 A2 BR 112012029881A2 BR 112012029881 A BR112012029881 A BR 112012029881A BR 112012029881 A BR112012029881 A BR 112012029881A BR 112012029881 A2 BR112012029881 A2 BR 112012029881A2
Authority
BR
Brazil
Prior art keywords
hcv
treatment
envelope
hcv infection
combination
Prior art date
Application number
BR112012029881A
Other languages
English (en)
Inventor
Baumert Thomas
Original Assignee
Inserm (Institut National De La Santé De La Recherche Médicale)
Université De Strasbourg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inserm (Institut National De La Santé De La Recherche Médicale), Université De Strasbourg filed Critical Inserm (Institut National De La Santé De La Recherche Médicale)
Publication of BR112012029881A2 publication Critical patent/BR112012029881A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

combinação de anticorpos anti-envelope e anticorpos anti-receptor para o tratamento e a presenção de infecção por hcv.a presente invenção fornece combinações de anticorpos para utilização no tratamento ou prevenção de infecção por hcv. em particular, são fornecidas combinações que compreendem pelo menos um anticorpos anti-envelope hcv e pelo menos um anticorpo anti-receptor hcv, em que o anticorpo anti-envelope hcv e o anticorpo anti-receptor hcv atuam de uma maneira altamente sinérgica para inibir a entrada de hcv em células suscetíveis. também são fornecidas composições farmacêuticas e kits compreendendo tais combinações e métodos de utilização destas composições e kits para o tratamento ou prevenção de infecção por hcv.
BR112012029881A 2010-05-25 2011-05-25 combinação de anticorpos anti-envelope e anticorpos anti-receptor para o tratamento e a presenção de infecção por hcv BR112012029881A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10305546 2010-05-25
PCT/EP2011/058538 WO2011147863A1 (en) 2010-05-25 2011-05-25 Combination of anti-envelope antibodies and anti-receptor antibodies for the treatment and prevention of hcv infection

Publications (1)

Publication Number Publication Date
BR112012029881A2 true BR112012029881A2 (pt) 2019-09-24

Family

ID=43064784

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012029881A BR112012029881A2 (pt) 2010-05-25 2011-05-25 combinação de anticorpos anti-envelope e anticorpos anti-receptor para o tratamento e a presenção de infecção por hcv

Country Status (6)

Country Link
US (1) US20130129676A1 (pt)
EP (1) EP2575885A1 (pt)
CN (1) CN103429265A (pt)
BR (1) BR112012029881A2 (pt)
CA (1) CA2800734A1 (pt)
WO (1) WO2011147863A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014033266A1 (en) * 2012-08-31 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection
WO2014116749A1 (en) * 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
EP3070103A1 (en) * 2015-03-19 2016-09-21 Institut Hospitalier Universitaire De Strasbourg Anti-Claudin 1 monoclonal antibodies for the prevention and treatment of hepatocellular carcinoma

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6150134A (en) 1994-07-29 2000-11-21 Innogenetics, N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US6538114B1 (en) 1996-04-19 2003-03-25 Karolina Innovations Ab Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen
US6747136B2 (en) 1996-04-19 2004-06-08 Karolinska Innovations Ab Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen
CN101088561A (zh) 1998-07-21 2007-12-19 展马博联合股份有限公司 抗丙型肝炎病毒抗体及其用途
US6692908B1 (en) * 1998-11-05 2004-02-17 Stanford University Prevention and treatment of HCV infection employing antibodies that inhibit the interaction of HCV virions with their receptor
WO2001058459A1 (en) 2000-02-14 2001-08-16 Mitsubishi Pharma Corporation Remedies for hepatitis c
IL139217A0 (en) 2000-03-13 2001-11-25 Applied Research Systems Monoclonal antibodies to the human ldl receptor, their production and use
US7315809B2 (en) * 2000-04-24 2008-01-01 Microsoft Corporation Computer-aided reading system and method with cross-language reading wizard
AU750296B2 (en) 2000-06-23 2002-07-11 F. Hoffmann-La Roche Ag Antibodies against SEMP1, methods for their production and uses thereof
WO2002048388A2 (en) 2000-10-25 2002-06-20 Vincent Agnello Method of inhibiting infection by hcv, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood preventing viral entry into a cell
EP1765869B1 (en) * 2004-07-08 2015-05-20 JV Bio S.r.l Antigen binding proteins directed against scavenger receptor b1 that inhibit hcv replication
US7842500B2 (en) 2005-03-31 2010-11-30 Seikagaku Corporation Anti-heparan sulfate antibody, method for detection of heparan sulfate, and kit for detection of heparan sulfate
CA2649962A1 (en) 2006-05-04 2007-11-15 The Rockefeller University Hcv coreceptor and methods of use thereof
ES2529511T3 (es) * 2008-09-25 2015-02-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticuerpos monoclonales anti-claudina 1 para la inhibición de la infección por virus de la hepatitis C
JP2012512261A (ja) * 2008-12-17 2012-05-31 ジェネンテック， インコーポレイテッド Ｃ型肝炎ウイルス併用療法

Also Published As

Publication number Publication date
CA2800734A1 (en) 2011-12-01
EP2575885A1 (en) 2013-04-10
WO2011147863A1 (en) 2011-12-01
CN103429265A (zh) 2013-12-04
US20130129676A1 (en) 2013-05-23

Similar Documents

Publication Publication Date Title
PH12018501891A1 (en) Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
BRPI0618451A2 (pt) derivados de piridopirazina, seu uso, composição farmacêutica e estojo
BR112013002484A2 (pt) composto, composição farmacêutica, métodos para tratar esclerose múltipla e artrite reumatoide, e, uso de um composto.
TW201129378A (en) Materials and methods for treating or preventing HER-3 associated diseases
BR112013020500A8 (pt) anticorpo isolado, recombinante ou purificado
EA201791850A1 (ru) Борсодержащие малые молекулы
BR112012010270A2 (pt) mentisulfonilmetano (msm) para tratamento de micro-organismos resistentes a fármaco
BR112015014333A8 (pt) compostos antivirais, seu uso e composição farmacêutica que os compreende
BRPI0921999B8 (pt) uso de uma quantidade terapeuticamente eficaz de células tronco placentárias
ECSP099634A (es) Derivados de piridazinona útiles como inhibidores de glucano sintasa
BR112014015908A2 (pt) composição
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
ECSP099685A (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
BRPI0906478B8 (pt) anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende
BR112013032711A2 (pt) composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase
BR112013025630A2 (pt) derivados de piridopirazina e seu uso
BR112014027991A2 (pt) agentes para neutralização de influenza
BR112015017241A8 (pt) composto, composição farmacêutica, uso do composto e da composição farmacêutica e kit
CL2009002129A1 (es) Derivados carboxiamida de lantibioticos; proceso de preparacion de dichos lantibioticos; composicion farmaceutica que lo contiene; utiles en el tratamiento de infecciones bacterianas.
BR112014008616A2 (pt) compostos antivirais
IN2014CN00572A (pt)
BR112014005773A2 (pt) composições derivadas de hyr1 e métodos of tratamento usando as mesmas
BRPI0711885A2 (pt) Aminotiazóis e seus usos
EA201171414A1 (ru) Ингибиторы белков семейства iap

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.